Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone - A novel antiarrhythmic agent

European Journal of Clinical Pharmacology

Volumn 50, Issue 4, 1996, Pages 315-319

  Koytchev, R ^a   Alken, R G ^a   Mayer, O ^b   Smith, I ^c   Greenwood, M ^c  

^a Coop Clin Drug R and D ^*  (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Hazleton Europe   (United Kingdom)

Author keywords

Bioavailability; Diprafenone; antiarrhythmics; Foods; Human; Pharmacokinetics

Indexed keywords

ANTIARRHYTHMIC AGENT; DIPRAFENONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FOOD-DRUG INTERACTIONS; HUMANS; MALE; PROPAFENONE;

EID: 0029895761     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050115     Document Type: Article

References (12)

1. + channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone. J Membr Biol 102: 105-119
2. Greenberg S, Cantor E, Paul J (1989) β-adrenoreceptor blocking activity of diprafenone in anesthezied dogs : comparison with propafenone and propranolol. J Cardiovasc Pharmacol 14:444-453
3. Thormann J, Kramer W, Kremer P, Schlepper M (1989) Influence of the new class I antiarrhythmic agent diprafenone on the end systolic pressure-volume relationship (conductance technique). Cardiovasc Drugs Ther 3:145-154
4. Kunze KP, Schlüter M, Geiger M, Kuck KH (1989) Diprafenone for treatment of Wolff- Parkinson-White Syndrome. Cardiovasc Drugs Ther 3:73-79
5. Kunze KP, Rubart M, Stellbrink C, König B, Hanrath P (1991) Erfolgreiche Unterdrückung von AV-Knoten-Reentry-Tachykardien durch Diprafenon. Zeit Kardiol 80(6):44
6. Trenk D, Wagner F, Jähnchen E (1989) Pharmakokinetik von Diprafenon am Menschen. In: Bender F. Gülker H (eds) Neue Aspekte in der Therapie mit Antiarrhythmika. Steinkopf. Darmstadt
7. Mahgoub A, Dring LG, Idle JR, Lancaster R. Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2(8038): 584-586
8. Axelson JE, Chan G L-Y, Kirsten, EB (1987) Food increases the bioavailability of propafenone. Br J Clin Pharmacol 23:735-741
9. Greenberg S, Luisi A (1989) General pharmacology of diprafenone, a new class Ic antiarrhythmic agent and 5-hydroxydiprafenone, an active metabolite. Drug Dev Res 17:35-50
10. Groschner K, Lindner W, Schnedl H, Kukowetz WR (1991) The effects of the stereoisomers of propafenone and dipragenone in guinea-pig heart. Br J Pharmacol 102:669-674
11. Gülkner H, Heuer H, Thale J, Behrenbeck T (1987) Elektrophysiologische und hämodynamische Wirkungen der neuen antiarrhythmischen Substanz Diprafenon. Z Kardiol 76:411-414
12. Hauschke D, Steinijans VW, Diletti E (1990) A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28(2): 72-78